{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:51:48Z","timestamp":1780321908664,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T00:00:00Z","timestamp":1559952000000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Pediatric Cardiology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ppedcard.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T10:35:22Z","timestamp":1528454122000},"page":"27-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Differential response to heart failure medications in children"],"prefix":"10.1016","volume":"49","author":[{"given":"Shelley D.","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen C.","family":"Sucharov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen C.","family":"Woulfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ppedcard.2018.01.011_bb0005","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/CIRCHEARTFAILURE.110.959882","article-title":"Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras","volume":"4","author":"Cubbon","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"13","key":"10.1016\/j.ppedcard.2018.01.011_bb0010","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jacc.2009.11.059","article-title":"The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy","volume":"55","author":"Kantor","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.ppedcard.2018.01.011_bb0015","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.296.15.1867","article-title":"Incidence, causes, and outcomes of dilated cardiomyopathy in children","volume":"296","author":"Towbin","year":"2006","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ppedcard.2018.01.011_bb0020","first-page":"1535","article-title":"Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines","volume":"29","author":"Kantor","year":"2013","journal-title":"Can J Cardiol"},{"issue":"9","key":"10.1016\/j.ppedcard.2018.01.011_bb0025","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.healun.2014.06.002","article-title":"The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: executive summary","volume":"33","author":"Kirk","year":"2014","journal-title":"J Heart Lung Transplant"},{"issue":"24","key":"10.1016\/j.ppedcard.2018.01.011_bb0030","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1161\/CIRCULATIONAHA.106.635128","article-title":"Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study","volume":"114","author":"Daubeney","year":"2006","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ppedcard.2018.01.011_bb0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.04.035","article-title":"Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation","volume":"44","author":"Tsirka","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ppedcard.2018.01.011_bb0040","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/jama.298.10.1171","article-title":"Carvedilol for children and adolescents with heart failure: a randomized controlled trial","volume":"298","author":"Shaddy","year":"2007","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.ppedcard.2018.01.011_bb0045","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"issue":"9377","key":"10.1016\/j.ppedcard.2018.01.011_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ppedcard.2018.01.011_bb0055","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s00246-010-9700-2","article-title":"Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol","volume":"31","author":"Petko","year":"2010","journal-title":"Pediatr Cardiol"},{"issue":"6 Pt 2","key":"10.1016\/j.ppedcard.2018.01.011_bb0060","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/0002-8703(91)90832-3","article-title":"Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States","volume":"121","author":"Anderson","year":"1991","journal-title":"Am Heart J"},{"issue":"13","key":"10.1016\/j.ppedcard.2018.01.011_bb0065","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJM198309293091302","article-title":"Evaluation of a new bipyridine inotropic agent\u2014milrinone\u2014in patients with severe congestive heart failure","volume":"309","author":"Baim","year":"1983","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ppedcard.2018.01.011_bb0070","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0735-1097(86)80231-5","article-title":"Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure","volume":"7","author":"Grose","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ppedcard.2018.01.011_bb0075","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/0002-8703(91)90154-A","article-title":"Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The western enoximone study group","volume":"121","author":"Narahara","year":"1991","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.ppedcard.2018.01.011_bb0080","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ppedcard.2018.01.011_bb0085","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","article-title":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","volume":"41","author":"Felker","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.ppedcard.2018.01.011_bb0090","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ppedcard.2018.01.011_bb0095","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/00003246-199609000-00010","article-title":"Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan intravenous milrinone investigators","volume":"24","author":"Seino","year":"1996","journal-title":"Crit Care Med"},{"issue":"5","key":"10.1016\/j.ppedcard.2018.01.011_bb0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.healun.2007.02.004","article-title":"Home inotropic therapy in children","volume":"26","author":"Berg","year":"2007","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.ppedcard.2018.01.011_bb0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cardfail.2005.11.001","article-title":"Outpatient continuous parenteral inotropic therapy as bridge to transplantation in children with advanced heart failure","volume":"12","author":"Price","year":"2006","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.ppedcard.2018.01.011_bb0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/CIRCHEARTFAILURE.114.001528","article-title":"Intravenous home inotropic use is safe in pediatric patients awaiting transplantation","volume":"8","author":"Birnbaum","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.ppedcard.2018.01.011_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/eurheartj\/ehs229","article-title":"Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy","volume":"35","author":"Miyamoto","year":"2014","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ppedcard.2018.01.011_bb0120","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/01.RES.87.12.1172","article-title":"The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3\u2032-kinase","volume":"87","author":"Chesley","year":"2000","journal-title":"Circ Res"},{"issue":"22","key":"10.1016\/j.ppedcard.2018.01.011_bb0125","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1161\/01.CIR.100.22.2210","article-title":"Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein","volume":"100","author":"Communal","year":"1999","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ppedcard.2018.01.011_bb0130","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1152\/japplphysiol.00627.2013","article-title":"beta-Adrenergic receptor antagonism in mice: a model for pediatric heart disease","volume":"115","author":"Sucharov","year":"1985","journal-title":"J Appl Physiol"},{"issue":"1","key":"10.1016\/j.ppedcard.2018.01.011_bb0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCHEARTFAILURE.114.001218","article-title":"Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy","volume":"8","author":"Nakano","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.ppedcard.2018.01.011_bb0140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cardfail.2016.07.429","article-title":"Cardiac adenylyl cyclase and phosphodiesterase expression profiles vary by age, disease, and chronic phosphodiesterase inhibitor treatment","volume":"23","author":"Nakano","year":"2017","journal-title":"J Card Fail"},{"issue":"5","key":"10.1016\/j.ppedcard.2018.01.011_bb0145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1388-9842(03)00109-0","article-title":"Plasma catecholamine levels parallel severity of heart failure and have prognostic value in children with dilated cardiomyopathy","volume":"5","author":"Venugopalan","year":"2003","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"10.1016\/j.ppedcard.2018.01.011_bb0150","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94382","article-title":"Pediatric and adult dilated cardiomyopathy represent distinct pathological entities","volume":"2","author":"Patel","year":"2017","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.ppedcard.2018.01.011_bb0155","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cardfail.2016.11.006","article-title":"Fibrosis and fibrotic gene expression in pediatric and adult patients with idiopathic dilated cardiomyopathy","volume":"23","author":"Woulfe","year":"2017","journal-title":"J Card Fail"},{"issue":"14","key":"10.1016\/j.ppedcard.2018.01.011_bb0160","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94249","article-title":"Pediatric dilated cardiomyopathy hearts display a unique gene expression profile","volume":"2","author":"Tatman","year":"2017","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.ppedcard.2018.01.011_bb0165","doi-asserted-by":"crossref","first-page":"H818","DOI":"10.1152\/ajpheart.00673.2016","article-title":"Exosomes from pediatric dilated cardiomyopathy patients modulate a pathological response in cardiomyocytes","volume":"312","author":"Jiang","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ppedcard.2018.01.011_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c3615","article-title":"US moves to improve health decisions","volume":"341","author":"Tunis","year":"2010","journal-title":"BMJ"}],"container-title":["Progress in Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1058981317301868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1058981317301868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:01:52Z","timestamp":1761008512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1058981317301868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":34,"alternative-id":["S1058981317301868"],"URL":"https:\/\/doi.org\/10.1016\/j.ppedcard.2018.01.011","relation":{},"ISSN":["1058-9813"],"issn-type":[{"value":"1058-9813","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential response to heart failure medications in children","name":"articletitle","label":"Article Title"},{"value":"Progress in Pediatric Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ppedcard.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}